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T
hemissionoftheAmericanDiabetes
Association is “to prevent and cure
diabetes and to improve the lives of
all people affected by diabetes.” Increas-
ingly, scientiﬁc and medical articles (1)
and commentaries (2) about diabetes in-
terventions use the terms “remission” and
“cure” as possible outcomes. Several ap-
proved or experimental treatments for
type 1 and type 2 diabetes (e.g., pancreas
or islet transplants, immunomodulation,
bariatric/metabolic surgery) are of cura-
tive intent or have been portrayed in the
media as a possible cure. However, deﬁn-
ing remission or cure of diabetes is not as
straightforward as it may seem. Unlike
“dichotomous”diseasessuchasmanyma-
lignancies, diabetes is deﬁned by hyper-
glycemia, which exists on a continuum
and may be impacted over a short time
frame by everyday treatment or events
(medications, diet, activity, intercurrent
illness). The distinction between success-
ful treatment and cure is blurred in the
case of diabetes. Presumably improved or
normalized glycemia must be part of the
deﬁnition of remission or cure. Glycemic
measures below diagnostic cut points for
diabetes can occur with ongoing medica-
tions (e.g., antihyperglycemic drugs, im-
munosuppressive medications after a
transplant), major efforts at lifestyle
change, a history of bariatric/metabolic
surgery, or ongoing procedures (such as re-
peated replacements of endoluminal de-
vices). Do we use the terms remission or
cure for all patients with normal glycemic
measures, regardless of how this is
achieved?
A consensus group comprised of ex-
perts in pediatric and adult endocrinol-
ogy, diabetes education, transplantation,
metabolism, bariatric/metabolic surgery,
and (for another perspective) hematolo-
gy-oncology met in June 2009 to discuss
theseissues.Thegroupconsideredawide
variety of questions, including whether it
is ever accurate to say that a chronic ill-
nessiscured;whatthedeﬁnitionsofman-
agement, remission, or cure might be;
whether goals of managing comorbid
conditions revert to those of patients
without diabetes if someone is “cured”;
and whether screening for diabetes com-
plications needs to continue in the
“cured”patient.Sincelittleornoscientiﬁc
or actuarial evidence exists to inform the
group’s discussions, consensus was difﬁ-
cult to attain in a number of areas. The
opinions and recommendations ex-
pressed herein are those of the authors
and not the ofﬁcial position of the Amer-
ican Diabetes Association.
Medically,curemaybedeﬁnedasres-
torationtogoodhealth,whileremissionis
deﬁned as abatement or disappearance of
the signs and symptoms of a disease (3).
Implicit in the latter is the possibility of
recurrence of the disease. Many clinicians
consider true cure to be limited to acute
diseases.Infectiousdiseasescouldbeseen
as a model: acute bacterial pneumonia
can be cured with antibiotics, but HIV in-
fection, currently, can at best be stated to
be in remission or converted to a chronic
disease. The consensus group considered
the history of childhood acute lymphoblas-
tic leukemia, which evolved from a uni-
formlyfataldiseasetoonethatcouldbeput
into remission to one that can now often be
considered cured (4). Conversely, chronic
myelocytic leukemia is now considered to
be in prolonged remission, but not cured,
with therapies such as imatinib.
For a chronic illness such as diabetes,
it may be more accurate to use the term
remission than cure. Current or potential
future therapies for type 1 or type 2 dia-
betes will likely always leave patients at
risk for relapse, given underlying patho-
physiologic abnormalities and/or genetic
predisposition. However, terminology
suchas“prolongedremission”isprobably
less satisfactory to patients than use of the
more hopeful and deﬁnitive term “cure”
aftersomeperiodoftimehaselapsed.Ad-
ditionally, if cure means remission that
lasts for a lifetime, then by deﬁnition a
patient could never be considered cured
while still alive. Hence, it may make sense
operationally to consider prolonged remis-
sion of diabetes essentially equivalent to
cure. This is analogous to certain cancers,
wherecureisdeﬁnedascompleteremission
of sufﬁcient duration that the future risk of
recurrence is felt to be very low.
Abnormal glucose metabolism lead-
ing to hyperglycemia deﬁnes the disease
diabetes, yet hyperglycemia exists on a
continuum and the diagnosis of the dis-
easeoccursatlevelssufﬁcientlyhightobe
associatedwiththediabetes-speciﬁccom-
plication retinopathy. Should absence of
the disease diabetes be deﬁned as glucose
values considered within the normal
range, sub-diabetic but not necessarily
normal glucose values, or the complete
absence of underlying abnormal physiol-
ogy such as insulin resistance or -cell
dysfunction or loss?
The group modeled its consensus deﬁ-
nitions somewhat on terminology that
exists for certain malignancies, with
hyperglycemia analogous to tumor load.
Cancer may initially be put into remission,
either partial (substantial reduction in tu-
mor load) or complete (no evidence of
tumor). Eventually, the duration of a
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Division of Endocrinology, Department of Medicine, University of North Carolina School of
Medicine,ChapelHill,NorthCarolina;the
2DepartmentofPediatrics,YaleUniversitySchoolofMedicine,
New Haven, Connecticut;
3Pennington Biomedical Research Center, Louisiana State University System,
Baton Rouge, Louisiana; the
4University of Warwick, Warwick Medical School, Coventry, U.K.; the
5Department of Endocrinology & Metabolism, Section of Metabolic Diseases and Diabetes, University
of Pisa, Pisa, Italy; the
6Section of Endocrinology, Department of Medicine, Yale University School of
Medicine, New Haven, Connecticut;
7Nebraska Medical Center, Omaha, Nebraska; the
8Division of
Hematology/Oncology, Department of Medicine, and the Wilmot Cancer Center, University of Rochester
School of Medicine, Rochester, New York;
9Paciﬁc Northwest Diabetes Research Institute and University
of Washington, Seattle, Washington; the
10Section of Metabolic Surgery, Department of Surgery, Weill
Cornell Medical College-New York Presbyterian Hospital, New York, New York; and the
11American
Diabetes Association, Alexandria, Virginia.
Corresponding author: M. Sue Kirkman, skirkman@diabetes.org.
DOI: 10.2337/dc09-9036
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
Reviews/Commentaries/ADA Statements
CONSENSUS STATEMENT
care.diabetesjournals.org DIABETES CARE, VOLUME 32, NUMBER 11, NOVEMBER 2009 2133complete remission is felt to be sufﬁcient
suchthattheriskofrecurrenceislikelytobe
low, and such a prolonged remission might
operationally be considered a cure. How-
ever, unlike tumor size in people with can-
cer, glucose levels in people with diabetes
may ﬂuctuate greatly from day to day. In a
patient with type 2 diabetes, for example,
improved or normal glycemia that occurs
after only a few days of a stringent diet
should certainly not be considered remis-
sion. Otherwise, patients could be in and
out of remission constantly. The minimum
duration of improved or normal glycemia
that must occur before being labeled remis-
sion was the subject of great debate, and in
theendthegroupconsensuswastobecon-
servative. Additionally, although glycemic
measures just below the diabetic cut points
could be deﬁned as absence of the disease
diabetes, the group considered impaired
glucose homeostasis a sign of minimal re-
sidual disease and hence only a partial re-
mission. The group was unable to reach a
consensus on the incremental value of oral
glucose tolerance testing, beyond the more
convenient A1C and FPG tests, in deﬁning
remission.
The authors agreed upon the follow-
ing deﬁnitions, which are the same for
type 1 and type 2 diabetes: Remission is
deﬁned as achieving glycemia below the
diabetic range in the absence of active
pharmacologic(anti-hyperglycemicmed-
ications, immunosuppressive medica-
tions) or surgical (ongoing procedures
such as repeated replacements of endolu-
minal devices) therapy. A remission can
be characterized as partial or complete.
Partialremissionissub-diabetichyper-
glycemia (A1C not diagnostic of diabetes
[6.5%], fasting glucose 100–125 mg/dl
[5.6–6.9 mmol/l]) of at least 1 year’s dura-
tion in the absence of active pharmacologic
therapy or ongoing procedures.
Complete remission is a return to “nor-
mal” measures of glucose metabolism (A1C
in the normal range, fasting glucose 100
mg/dl [5.6 mmol/l]) of at least 1 year’s du-
ration in the absence of active pharmaco-
logic therapy or ongoing procedures.
Remission of type 2 diabetes could be
attained, for example, after bariatric/
metabolic surgery or with lifestyle efforts
such as weight loss and exercise. Nondi-
abetic glycemia resulting from ongoing
medications or repeated procedures
(such as in the dynamic phase of band
adjustment after laparoscopic gastric
banding)wouldnotmeetthedeﬁnitionof
remission, as these interventions are con-
sidered treatment. Remission can be con-
sidered an outcome of devices (e.g., gastric
banding, endoluminal devices) only after
the patient has achieved a steady state and
no longer requires repeated adjustments
and/or replacements of the device. For type
1 diabetes, remission could potentially be
attained after immune modulating or islet-
replacement therapies that do not require
ongoing immunosuppression but not with
transplants that require ongoing immuno-
suppression or future therapies such as an
implanted artiﬁcial pancreas.
Prolonged remission is complete re-
mission that lasts for more than 5 years
and might operationally be considered a
cure. The 5-year period was chosen arbi-
trarily, since there are no actuarial data
indicating the likelihood of relapse over
various periods of time from the onset of
normoglycemia. It is recognized that the
risk of relapse likely remains higher for
peoplewithdiabetesinremissionthanfor
age-, sex-, BMI-, and ethnicity-matched
individuals who have never had diabetes.
In addition to hyperglycemia, diabe-
tes is characterized by speciﬁc (microvas-
cular) or nonspeciﬁc (cardiovascular)
complications. Diabetes management
includes treating cardiovascular risk fac-
tors, such as hypertension and dyslipide-
mia, often to more stringent goals than
those for patients who do not have diabe-
tes.Peoplewithdiabetesalsoneedregular
screenings for the microvascular compli-
cationsofthedisease,suchasretinopathy
and nephropathy. If a patient is in remis-
sion from diabetes, do they still require
diabetes-speciﬁc treatment goals and
screening protocols, and if so, for how
long? The consensus group considered
both issues to be a function of risk over
time. For cardiovascular disease, the very
high risk that diabetes imparts is unlikely
tobemodiﬁedquickly,ifever,byamelio-
ration of hyperglycemia, particularly if
the usual coexisting risk factors are still
present. For diabetes-speciﬁc complica-
tions such as retinopathy, risk for inci-
dent complications is likely to decline
signiﬁcantly with prolonged normogly-
cemia, while established complications
would likely need ongoing monitoring
indeﬁnitely.
In a partial or complete remission of
less than 5 years’ duration, the goals for
treatment of comorbidities (hyperten-
sion, dyslipidemia) should remain the
same as for those with diabetes (e.g.,
blood pressure goal 130/80 mmHg).
When complete remission exceeds 5
years, goals appropriate for a patient
without diabetes could be considered,
as long as the patient remained without
recurrence of diabetes and without car-
diovascular events.
In a partial or complete remission of
less than 5 years’ duration, the patient
Table 1—Summary of consensus deﬁnitions and recommendations
Deﬁnitions
Partial remission
Hyperglycemia below diagnostic thresholds for diabetes
At least 1 year’s duration
No active pharmacologic therapy or ongoing procedures
Complete remission
Normal glycemic measures
At least 1 year’s duration
No active pharmacologic therapy or ongoing procedures
Prolonged remission
Complete remission of at least 5 years’ duration
Recommendations
Treatment goals for comorbid conditions
Same as those for patients with diabetes for patients with partial or complete remission
of less than 5 years’ duration
With prolonged remission, could consider goals appropriate for patients without
diabetes, as long as there is no recurrence of diabetes and no cardiovascular disease
Screening for microvascular complications
Same protocols as those for patients with diabetes for patients with partial or complete
remission of less than 5 years’ duration
With prolonged remission, could consider screening at reduced frequency depending on
the status of each complication
With prolonged remission, only consider stopping screening for a particular
complication completely if there is no history of that complication
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cations of diabetes at the same fre-
quency as when diabetes was present.
Once a complete remission exceeds 5
years, complication screening might oc-
cur at a reduced frequency (depending
on the status of each complication).
Completely stopping screening for a
particular complication should be con-
sidered only if there is no history of that
complication.
These deﬁnitions and consensus rec-
ommendations, summarized in Table 1,
are based on what the consensus group
felttobereasonablegiventhetherapiesof
today. The authors hope that this article
will engender active discussion in the
ﬁeld. As new therapies of curative intent
emerge for type 1 and type 2 diabetes and
actuarial and scientiﬁc evidence regard-
ing prognosis builds, these issues will
surely require further deliberation.
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